perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1 Development of an effective immune response in adults with Down Syndrome

2 after SARS-CoV-2 vaccination

3

- 4 Laura Esparcia-Pinedo^{1(*)}, Ayla Yarci-Carrión^{2(*)}, Gloria Mateo-Jiménez³, Noelia
- 5 Ropero¹, Laura Gómez-Cabañas⁴, Ángel Lancho-Sánchez⁴, Enrique Martín-Gayo^{1,5},
- 6 Francisco Sanchez-Madrid^{1,5}, Fernando Moldenhauer⁶, Ainhoa Gutiérrez-Cobos^{2(#)},
- 7 Diego Real de Asúa^{5,6(#)}, Arantzazu Alfranca^{1,5(#,&)}.

8

- 91. Immunology Department, Hospital Universitario de La Princesa, Instituto de
- 10 Investigación Sanitaria Princesa, Madrid, Spain
- 112. Microbiology Department, Hospital Universitario de La Princesa, Instituto de
- 12 Investigación Sanitaria Princesa, Madrid, Spain
- 133. Fundación de Investigación Biomédica del Hospital Universitario de La Princesa,
- 14 Instituto de Investigación Sanitaria Princesa, Madrid, Spain
- 154. Biobanco, Fundación de Investigación del Hospital Universitario de La Princesa,
- 16 Instituto de Investigación Sanitaria Princesa, Madrid, Spain
- 175. Department of Medicine, School of Medicine, Universidad Autónoma de Madrid,
- 18 Madrid, Spain
- 196. Internal Medicine Department, Hospital Universitario de La Princesa, Instituto de
- 20 Investigación Sanitaria Princesa, Madrid, Spain
- 21
- 22 ^(*) These authors share first authorship
- 23 (#) These authors share senior authorship

24 ^(&) Corresponding author:

- 25 Arantzazu Alfranca
- 26 Immunology Department
- 27 Hospital Universitario de La Princesa
- 28 Dieo de León 62
- 29 28006Madrid, Spain
- 30 Email: <u>mariaaranzazu.alfranca@salud.madrid.org</u>
- 31 T: +34 915202200
- 32
- 33

SUMMARY 34

35 The work shows the cellular and humoral responses to SARS-CoV-2 vaccination of individuals with Down syndrome (DS) after one to three (V1) and six (V2) months. An 36 37 effective immune response after six months was observed in 98% of DS individuals.

38

39 ABSTRACT

40

Immune dysregulation in individuals with Down syndrome (DS) leads to an increased 41 risk for hospitalization and death due to COVID-19 and may impair the generation of 42 43 protective immunity after vaccine administration. The cellular and humoral responses of 55 DS patients who received a complete SARS-CoV-2 vaccination regime at one to three 44 45 (V1) and six (V2) months were characterised. SARS-CoV-2-reactive CD4+ and CD8+ T lymphocytes with a predominant Th1 phenotype were observed at V1, and increased at 46 47 V2. Likewise, a sustained increase of SARS-CoV-2-specific circulating Tfh (cTfh) cells was observed one to three months after vaccine administration. Specific IgG antibodies 48 49 against SARS-CoV-2 S protein were detected in 96% and 98% of subjects at V1 and V2, respectively, though IgG titers decreased significantly between both timepoints. 50 51

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

52 **INTRODUCTION**

53 The new coronavirus disease (COVID-19) due to SARS-CoV-2 is a global health 54 emergency since March 2020. Although COVID-19 entails no or mild symptoms in most 55 individuals, several at-risk patient subgroups develop a severe form of the disease, 56 leading to acute respiratory distress syndrome (ARDS) (Brodin, 2021; Ruan et al., 2020). 57 Individuals with Down syndrome (DS), the most frequent chromosomal abnormality 58 worldwide, are particularly vulnerable to the disease, with a 4-fold increased risk for 59 COVID-19-related hospitalization and a 3 to 10-fold increased risk for COVID-19-related mortality (Clift et al., 2021; Hüls et al., 2021; Wadman, 2020). 60

61

Although this increase can be partially attributed to a higher prevalence of comorbidities 62 63 associated with a poorer COVID-19-related prognosis, such as obesity, congenital heart disease (CHD) or respiratory diseases (Perera et al., 2020; Real de Asua et al., 2021) 64 the susceptibility of this population to SARS-CoV-2 can be further explained by the 65 immune dysregulation observed in DS. These individuals display immune features which 66 promote the development of autoinflammatory and autoimmune conditions, and lead to 67 68 an increase in the incidence of infections (Huggard et al., 2020). DS patients show higher levels of IFN-stimulated genes, which explain their higher basal levels of IFN- α signaling 69 and hypersensitivity to IFN stimulation (Chung et al., 2021). Indeed, four subunits of IFN 70 71 receptors are encoded on HSA21 (IFNAR1, IFNAR2, IFNGR2, and IL10RB), and an increase in IFNAR1 and IFNAR2 expression in different cell types from DS donors has 72 been described (Kong et al., 2020). Cells from DS patients also present variable degrees 73 74 of increased IFN-I proximal signaling, such as higher levels of pSTAT1 (Malle and 75 Bogunovic, 2021). Furthermore, the increased expression of TMPRSS2, which primes 76 the viral S protein for entry into host cells and is also encoded in HSA21, may facilitate 77 the infection of target cells by SARS-CoV-2, while NLRP3 downregulation and increased 78 IL-10 production could be involved in the higher risk of bacterial infectious complications 79 in these patients (De Toma and Dierssen, 2021; Espinosa, 2020). DS individuals also have high basal levels of proinflammatory cytokines like IL-2, IL-6, or TNF- α , which may 80 81 enhance the "cytokine storm" that underlies ARDS in this condition (Espinosa, 2020). 82 Although the overall effect of these alterations seems deleterious and provides some 83 proof for the worse outcomes following SARS-CoV-2 infection, the net balance between all these interplaying factors is far from clear. Indeed, a decrease in IFNAR2 has been 84 associated with worse COVID-19 outcome (Pairo-Castineira et al., 2021), hence this 85 86 mechanism would theoretically contribute to a better evolution of COVID-19 infections in DS patients. 87

88

89 This immune dysregulation may impair the generation of protective immunity after vaccine administration in individuals with DS. In fact, though people with DS usually 90 91 develop protective antibody responses after vaccination, overall antibody levels tend to 92 be lower and decline faster than in individuals without DS (Joshi et al., 2011). Due to 93 their excess mortality risk and these concerns over vaccine protection, most countries 94 have included adults with DS, especially those over 40 years, in prioritized vaccination 95 groups (Hüls et al., 2020). However, data on the immune response elicited by SARS-96 CoV-2 vaccines in the DS population are lacking, and the degree of protection achieved 97 is unknown. A thorough characterization of the humoral and cellular immunity 98 mechanisms underlying the response of individuals with DS to COVID-19 vaccines is 99 needed to appropriately tailor future vaccination campaigns for this vulnerable 100 population. Moreover, this knowledge may also shed light onto general immune mechanisms involved in the response to SARS-CoV-2, and in the development of post-101 102 vaccination responses.

103

104 We performed a characterization of cellular and humoral responses developed in DS 105 patients at one to three (V1) and six (V2) months after two-dose SARS-CoV-2

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

vaccination. We provide evidence of the presence of SARS-CoV-2-reactive CD4+ and
 CD8+ T lymphocytes with a predominant Th1 phenotype in V1, which increased in V2.
 Likewise, a sustained increase of SARS-CoV-2-specific circulating Tfh (cTfh) cells was
 observed in these patients one to three months after vaccine administration. Specific IgG
 antibodies against SARS-CoV-2 S protein were detected in V1, which significantly
 decreased in V2.

112

113 **RESULTS AND DISCUSSION**

114

115 **T cell response to SARS-CoV vaccination in DS donors**

To assess immune response elicited by SARS-CoV-2 vaccine in DS, we recruited 55 116 117 donors whose demographic and clinical characteristics are shown in Table 1. These donors were inoculated with two doses of a SARS-CoV-2 vaccine following the 118 119 recommended schedule (vaccine types, described in Table 1), and both T cell and 120 antibody responses were analyzed before vaccine administration (V0), one to three 121 months (V1) and six months (V2) after second vaccination. Fifty-one subjects (51/55, 93%) were enrolled after having received at least one vaccination dose. To avoid any 122 123 delay in official vaccination strategies, we admitted the use in these cases of biobank-124 stored samples (from earlier than February 2020) as baseline (V0). Median time 125 (interguartile range) from the last dose of the recommended vaccination schedule to the first blood extraction (V1) was 62 (42-70) days, and 159 (150-172) days to the second 126 127 blood extraction (V2).

We determined the presence of SARS-CoV-2-specific T cells in V0, V1 and V2. To assess the percentage of responsive T cells, we used an activation-induced marker (AIM) assay based on the detection of CD4+ OX40/CD137 double positive and CD8+ CD69/CD137 double positive cells, after 24h in the presence of peptide pools from SARS-CoV-2 (NCAP, S1, S2, RBD domain, VME1 and Mpro proteins for V0 and S1, S2, and RBD domain for V1 and V2). In all cases, we included a human actin-derived peptide pool as a negative control, and Staphylococcal enterotoxin B (SEB) as a positive control.

135 As shown in Fig.1, we found a predominant CD4+ response (73.21% patients with 136 specific CD4+ vs.16.36% patients with specific CD8+ in V2), which is in line with previous data in non-DS individuals (Grifoni et al., 2020). Of note, CD4+ activation against S1 and 137 138 S2 was observed in a single pre-pandemic sample from V0 (Fig. 1A). We did not detect SARS-CoV-2-specific CD8+ lymphocytes in this baseline visit (Fig. 1B). SARS-CoV-2 S-139 140 responsive CD4+ cells have also been previously detected in healthy non-DS donors, and their presence is explained by a possible cross-reaction with common cold 141 142 coronaviruses or other pathogens which contain SARS-CoV-2 homologous sequences 143 (Woldemeskel et al., 2020). Interestingly, unlike our DS donors, NCAP-specific CD4+T 144 cells have been frequently identified in healthy non-DS donors (Mateus et al., 2020), a 145 finding which has been attributed by some authors to former exposure to SARS-CoV-2, 146 since no NCAP-responsive CD4+ cells have been observed in pre-pandemic samples 147 (Sekine et al., 2020). Because most V0 samples in our study were collected before the 148 beginning of the pandemic, previous asymptomatic contact with SARS-CoV-2 can be 149 reliably ruled out. In addition, it is conceivable that T cells recognizing NCAP might 150 display reduced functional avidity, which would impair their detection in our activation-151 dependent assay. This possibility could be further supported by a feasible defect in *in* 152 vitro T cell activation in DS patients, however lymphocytes from these individuals have 153 been shown to respond in vitro to SEB, CMV and VZV to a similar extent as non-DS 154 donors (Schoch et al., 2017).

After vaccination, the percentage of individuals with SARS-CoV-2-responsive T lymphocytes raised from 23.8% in V1 to 73.21% in V2 for CD4+, and from 8.93% in V1 to 16.36% in V2 for CD8+. We could detect vaccine-elicited specific CD4+ and CD8+

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

directed against S1, S2 and RBD, with a similar pattern in V1 and V2 (Fig. 1A, B). T cell
 responses seem to be delayed in comparison to non-DS donors, which usually reach a
 higher percentage of individuals with specific T cell immunity within 4-7 weeks post
 SARS-CoV-2 vaccine administration (Esparcia-Pinedo L et al., 2022).

162 SARS-CoV-2 mRNA vaccines are known to promote a Th1 reaction in the general 163 population (Sadarangani et al., 2021). Because individuals with DS usually present a 164 higher Th1/Th2 ratio than euploid donors, a finding related to an increase in baseline IFN γ levels in this population (Franciotta et al., 2006), we sought to determine whether 165 166 vaccination also resulted in Th1 predominant response in these patients. We evaluated T helper populations in SARS-CoV-2-specific CD4+ lymphocytes and found comparable 167 168 percentages of Th1 and Th2 in V1. However, a significant increase in Th1 but not Th2 169 could be observed in V2 (p<0.01). As a specificity control, we determined Th1 and Th2 distribution in SEB-stimulated CD4+ cells, and found no significant differences between 170 both subsets in either V1 and V2 (Fig. 2A). A similar pattern was detected regardless of 171 the peptide pool (S1 or S2) analyzed (Fig. 2B). In addition, we did not find gender 172 173 differences in Th1 and Th2 behavior, except for a significantly higher Th2 response in 174 V1 in male DS donors (Suppl. Fig. 2A). Of note, although Th1 increase in V2 could be 175 observed in all DS individuals, it was higher in patients < 40 years of age (Suppl. Fig. 176 2B).

177 T follicular helper cells (Tfh) constitute a specialized subset of CD4+ T cells that collaborates in the activation and proliferation of B cells and the generation of high-affinity 178 179 antibodies. In DS, normal counts of Tfh with a reduced B helper capacity have been reported. However other authors show increased percentages of IFN_y-secreting Tfh 180 181 (Tfh1), which are thought to promote autoimmune responses in these patients (Ottaviano 182 et al., 2020). In vaccinated DS donors, we found a SARS-CoV-2-specific cTfh population with sustained levels between V1 and V2 (Fig. 3A). PD-1hi cTfh are thought to represent 183 184 a subset of recently activated cTfh cells (Dan et al., 2021). Accordingly, we detected SARS-CoV-2-specific CD4+CXCR5+PD-1hi cells in V1 in DS donors, whose levels were 185 186 slightly reduced in V2 (Fig. 3A).

187 A population of CD8+CXCR5+ cells has been described which includes several functional subsets. Among them, a CD8+CXCR5+PD-1hi subset with Tfh-like properties 188 displays cytotoxic characteristics in germinal centers, and may support antibody 189 190 production in chronic infections and autoimmune conditions (Valentine and Hover, 2019). 191 This population has been recently reported to increase in acute immunization settings and collaborate in specific antibody response (Tyllis et al., 2021). We therefore 192 investigated the presence of SARS-CoV-2 specific CD8+CXCR5+PD-1hi cells in 193 194 vaccinated DS patients and found that these cells were already detectable in V1, and 195 their levels significantly increased in V2 (p<0.01) (Fig. 3B), suggesting that this cell 196 subset could also cooperate in antibody generation in DS individuals after vaccine 197 administration, although the actual functional significance of this population remains to 198 be determined. In sum, our results indicate that SARS-CoV-2 vaccination efficiently 199 induces the differentiation of specific populations that collaborate in an effective antibody 200 response.

201

202 Humoral response to SARS-CoV-2 vaccination in DS individuals

DS patients exhibit alterations in B lymphocyte maturation and function that may account for an impaired humoral response to vaccination. Transitional and mature naïve B cells are usually reduced by 50%, while numbers of switched memory B cells reach 10% of those found in non-DS counterparts (Carsetti et al., 2015). Similarly, a reduced frequency of switched memory B cells specific to vaccine antigens has been described in DS (Valentini et al., 2015). However, the degree of humoral response in DS individuals is highly variable among different vaccines. In this regard, influenza A/H1N1,

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

210 pneumococcal capsular polysaccharide, or hepatitis B virus vaccination only induce a 211 partial antibody response (Costa-Carvalho et al., 2006; Eijsvoogel et al., 2017), while 212 conjugated pneumococcal or Hepatitis A virus vaccines have been reported to elicit 213 adequate antibody titers. In our study, no patients were positive for anti-SARS-CoV-2 214 IgG before vaccination. We did find detectable titers of SARS-CoV-2 S protein specific 215 IgG in 96.4% of patients (53/55) at V1. Two patients did not develop anti-S IgG antibodies 216 at V1, one of which showed detectable titers of IgG at V2. The percentage of positive 217 donors was similar at V2, when detectable titers of S protein-specific IgG were observed 218 in 98.1% of patients (52/53, two patients with no data on humoral response at this 219 timepoint; Fig.4A and Supplementary Table 1).

220

221 A significant decrease in IgG titers was found in 92.6% of patients (50/54) between both 222 timepoints (Fig. 4B and Supplementary Table 1). Average specific IgG titers declined from 1520.84 BAU/mL in V1 to 780.88 BAU/mL in V2. This decrease was observed in 223 224 the whole sample, though it was only statistically significant in the subgroup of individuals 225 older than 40 years (Fig. 4C). Our results show an uncoupled humoral and cellular 226 response in these patients, with antibody titers peaking already at V1, whereas T cell 227 activation peaks at V2 (Fig.4). A dissociation between both arms of adaptive immunity 228 has also been described in euploid individuals infected with SARS-CoV-2, and the 229 development of an overt antibody response is not always accompanied by detectable T 230 cell specific activation (Grifoni et al., 2020).

231

232 Our findings show that an immune adaptive response is achieved in DS individuals three 233 months after SARS-CoV-2 vaccination lasting, at least, up to six months after 234 vaccination. The degree of protection conveyed by these vaccination-elicited 235 immunological changes should nonetheless be carefully interpreted. Recent reports still 236 show an increased hazard ratio for COVID-19 hospital admission (2.55-fold increase) 237 and mortality rate (12.7 fold increase) in DS patients, despite vaccination with one or two 238 doses of either ChAdOx1 nCoV-19 or BNT162b2 (Hippisley-Cox et al., 2021). It is likely 239 that other mechanisms beyond viral infection, and probably related to the intrinsic 240 proinflammatory status present in patients with DS, operate to lead to a worse outcome 241 even in vaccinated individuals. These indirect findings support the generalization of 242 current recommendations to promote booster doses in the DS population. Moreover, 243 because we observed a more robust response to vaccination in individuals with DS 244 younger than 40 years, we believe our results lend further support to the 245 recommendation of prioritizing the administration of an additional vaccine booster dose 246 preferably in adults with DS over 40 years.

247

Yet unexplored but interesting issues are whether and how long vaccine-elicited responses persist over time in these patients. We are currently collecting samples to assess the evolution of humoral end cellular immunity up to twelve months after vaccination. Meanwhile, DS individuals over 40 years are already being administered a third dose of mRNA SARS-CoV-2 vaccine in Spain at the time of this publication. Analyzing the impact of this additional booster dose in their immune response will also be of great interest.

255

256 MATERIALS AND METHODS

257

258 Study population259

This descriptive study was conducted with serological samples obtained from SD donors at La Princesa University Hospital, a tertiary level hospital in Madrid. Research subjects were consecutively recruited from those attending the Adult Down Syndrome outpatient unit, who consented to vaccination against SARS-CoV-2 during the 2021 COVID-19

vaccination season. The recruitment period ran from February 2021 to June 2021, and subject follow-up is ongoing at the time of this interim analysis.

Adults with DS over 18 years were considered eligible for participation in the study. DS 266 267 diagnosis was established with a karyotype or compatible typical phenotype. Because 268 the selection of a specific vaccine type (mRNA, adenoviral, etc) or regime depended on 269 local availability and on the directives issued by the Spanish Ministry of Health -which 270 have varied over time and between regions-, we determined that subject selection should 271 not be limited to any single vaccine type. Inclusion in this study did not influence 272 vaccination eligibility or regime, nor did it play a part in the usual clinical care received 273 by adults with DS.

Patients were not eligible to participate in the study if they had a history of prior anaphylactic reaction to other vaccines/vaccine components or had were limited in their mobility and had strong difficulties to complete follow-up (i.e., many individuals living in residential settings).

278 Detection of specific anti-SARS-CoV-2 IgG

279

All the samples were frozen at -20°C after extraction. This is a standard of care that allows future serological assessments in case of need. Antibody titers were obtained by *SARS CoV-2 IgG II QUANT Alinity (Abbott®)*. This assay is an automated, two-step immunoassay for the quantitative determination of IgG antibodies to SARS-CoV-2 against the spike receptor-binding domain (RBD) of SARS-CoV-2 in human serum using chemiluminescent microparticle immunoassay (CMIA).

SARS-CoV-2 IgG II Quant assay has demonstrated the ability to detect the spike RBDbased vaccine response in longitudinal samples from individuals both with and without
prior COVID-19 infection (Ebinger et al., 2021; Narasimhan et al., 2021; Prendecki et al.,
2021).

290 The interpretation of the results has been done following the criteria of the manufacturer, 291 considering a negative result when a result <7,1 BAU/ mL was obtained. A positive result 292 has been considered when a quantifiable result of ≥7.2 BAU/mL was obtained. The 293 system has an analytical measurement range of 2,98-5680 BAU/mL. When there is > 294 5870 BAU/mL in the serum, the system reports it as> 5870 BAU/mL. The company 295 reports a sensitivity of 99.3% and a specificity of 99.5% for this assay. We have 296 expressed our results in BAU/mL (Binding antibody unit/mL). In line with the WHO International Standard study, the mathematical relationship of Abbott AU/mL unit to WHO 297 298 would follow the equation: BAU/mL 0.142 × AU/mL BAU/mL unit = 299 (STANDARDIZATION).

300

301 **PBMC Isolation and Culture**

302 Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque (Pan-303 Biotech), following manufacturer's instructions, and cryopreserved in liquid N2 in fetal 304 bovine serum (HyClone TM) containing 10% DMSO (Inilab) and 1% penicillin/streptomycin (GIBCO) until use. For flow cytometry assays, 2x10⁵ cells per well 305 were cultured for 24h at 37°C and 5%CO2 atmosphere, in the presence of different 306 SARS-COV-2 peptide pools (PepMixTM; JPT Peptide Technologies). Pools included 307 peptides from S1, S2 and RBD from spike (S) protein, VME1 (membrane protein), NCAP 308 309 (nucleoprotein) and Mpro (Cys-like protease, nsp5) (1µg/ml) in V0, and S1, S2 and RBD for V1/V2. A positive control with staphylococcal enterotoxin B (SEB; Sigma Aldrich) 310 311 $(1\mu g/ml)$, and a negative control with human β -actin peptide pool (PepMixTM; JPT) 312 Peptide Technologies) (1µg/ml) were included.

313 Flow Cytometry

After stimulation, cells were incubated with anti-human CD3-PECy7/CD4-Pacific Orange/CD69-FITC/CXCR5-BV605/PD-1-BV786/CCR6-PerCP (BD Becton

Dickinson)/CD137-BV711/OX40-PE/CXCR3-APCH7 316 (Biolegend) for 30 min. 317 Subsequently, cells were washed and finally resuspended in 200µl PBS 1x. All the 318 samples were acquired on a BD FACSCanto II flow cytometer (BD Becton Dickinson). 319 The gating strategy for stimulated T cells is provided in Suppl Fig. 1: CD4+ T cells were 320 identified as positive for CD3 and CD4 markers. Activated CD4+ cells were defined as double positive for OX40 and CD137. SARS-CoV-2-responsive Th1 and Th2 were 321 322 defined as OX40+CD137+ cells within CXCR3+CCR6- and CXCR3-CCR6- subsets 323 respectively. SARS-CoV-2-specific cTfh cells were defined as OX40+CD137+ double 324 positive cells within CD4+CXCR5+ and CD4+CXCR5+PD-1hi populations. CD8+ T cells 325 were identified as positive for CD3 and negative for CD4 staining, and activated CD8+ defined as CD69 and CD137 double positive cells. Flow cytometry data were analyzed 326 327 using FlowJo software (BD Becton Dickinson).

Specific T cell response was determined by subtracting the percentage of either CD4+ OX40+CD137+ or CD8+ CD69+CD137+ in the presence of β -actin peptides from that obtained with SEB or SARS-CoV-2 peptides (specific percentage). A positive result was considered for samples with specific percentage equal or above the median two-fold standard deviation of all negative controls (0.82% for OX40/CD137 and 0.93% for CD69/CD137).

334 Ethical considerations

This project was approved by the institutional IRB at La Princesa University Hospital (register number: 4386), meets international standards of data protection and is in line with general good practice guidelines and those established in the Declaration of Helsinki.

339 Statistical analysis

340 Categorical data were described as frequencies (percentages) and quantitative 341 variables, as mean (SD) or median (IQR). Quantitative variables were represented in bar graphs as mean ± standard deviation (SD), or in box-and-whiskers plots. For comparison 342 343 between populations, analysis of variance was performed. To analyze statistically 344 significant differences in variables following a non-normal distribution, Kruskal-Wallis test 345 for unpaired samples and Friedman test for paired samples were used. The statistical significance threshold was set at p < 0.05. All data analyses were performed using Graph 346 347 Pad Prism 8 Software (GraphPad Software, USA, www.graphpad.com), R (version 4.0.0), and SPSS. 348

349

350 Online supplemental material

Supplemental material includes Supplemental Table 1 (detailed specific IgG titers in vaccinated DS patients), Supplemental Figure 1 (gating strategy for flow cytometry assays) and Supplemental Figure 2 (gender and age distribution of T helper subsets in vaccinated DS patients).

355

356 ACKNOWLEDGEMENTS

357 This work was supported by grants to A.A.: FIS PI19/01491 (Fondo de Investigación 358 Sanitaria del Instituto de Salud Carlos III with co-funding from the Fondo Europeo de 359 Desarrollo Regional FEDER) and Sociedad Cooperativa de Viviendas Buen Suceso. S.Coop.Mad. To A.A. and F.S-M.: CIBER Cardiovascular from the Instituto de Salud 360 361 Carlos III (Fondo de Investigación Sanitaria del Instituto de Salud Carlos III with co-362 funding from the Fondo Europeo de Desarrollo Regional; FEDER). To F.S-M.: "Fondos 363 Supera COVID19" (Banco de Santander and CRUE), "Ayuda Covid 2019" and 364 "Inmunovacter" REACT-UE (Comunidad de Madrid). DRA was supported by the Fondo 365 de Investigaciones Sanitarias (FIS grant PI19/00634, from the Ministerio de Economía y 366 Competitividad (Instituto de Salud Carlos III) and co-funded by The European Regional 367 Development Fund (ERDF) "A way to make Europe" and the Fondation Jérôme Lejeune

(grant no. 2021a-2069). FM is supported by the Jérôme Lejeune Foundation (grant no.
 2017b-1711). The Adult Down Syndrome Outpatient unit at Hospital Universitario de La
 Princesa is grateful to Licenciado don Jesús Coronado Hinojosa for his financial support
 of the research endeavors of our unit.

372 COMPETING INTERESTS

373 The authors declare no competing financial interests.

374 AUTHOR CONTRIBUTIONS

- Project coordination, original idea: AA, AG, DRA
- Subject recruitment and follow-up: FM, DRA
- Variable collection and database compilation: GM, AY, LE
- Initial sample processing, and sample collection preservation/storage: GM, AY, LE, NR
- Serological assays: AG, AY
- Cellular immunity activation assays: AA, LE, NR
- Lab coordination: AA, AG
- Statistical analysis and data mining: AG, AA, DRA
- Results evaluation, manuscript drafting and publication: All
- 384

385 **REFERENCES**

- Brodin, P. 2021. Immune determinants of COVID-19 disease presentation and severity. *Nat Med* 27:28-33.
- Carsetti, R., D. Valentini, V. Marcellini, M. Scarsella, E. Marasco, F. Giustini, A. Bartuli, A. Villani,
 and A.G. Ugazio. 2015. Reduced numbers of switched memory B cells with high terminal
 differentiation potential in Down syndrome. *Eur J Immunol* 45:903-914.
- Chung, H., P.H.R. Green, T.C. Wang, and X.F. Kong. 2021. Interferon-Driven Immune
 Dysregulation in Down Syndrome: A Review of the Evidence. *J Inflamm Res* 14:51875200.
- Clift, A.K., C.A.C. Coupland, R.H. Keogh, H. Hemingway, and J. Hippisley-Cox. 2021. COVID-19
 Mortality Risk in Down Syndrome: Results From a Cohort Study of 8 Million Adults. *Ann Intern Med* 174:572-576.
- Costa-Carvalho, B.T., R.M. Martinez, A.T. Dias, C.A. Kubo, P. Barros-Nunes, L. Leiva, D. Solé, M.M.
 Carneiro-Sampaio, C.K. Naspitz, and R.U. Sorensen. 2006. Antibody response to
 pneumococcal capsular polysaccharide vaccine in Down syndrome patients. *Braz J Med Biol Res* 39:1587-1592.
- 401 Dan, J.M., J. Mateus, Y. Kato, K.M. Hastie, E.D. Yu, C.E. Faliti, A. Grifoni, S.I. Ramirez, S. Haupt, A.
 402 Frazier, C. Nakao, V. Rayaprolu, S.A. Rawlings, B. Peters, F. Krammer, V. Simon, E.O.
 403 Saphire, D.M. Smith, D. Weiskopf, A. Sette, and S. Crotty. 2021. Immunological memory
 404 to SARS-CoV-2 assessed for up to 8 months after infection. *Science* 371:
- De Toma, I., and M. Dierssen. 2021. Network analysis of Down syndrome and SARS-CoV-2
 identifies risk and protective factors for COVID-19. *Sci Rep* 11:1930.
- 407 Ebinger, J.E., J. Fert-Bober, I. Printsev, M. Wu, N. Sun, J.C. Prostko, E.C. Frias, J.L. Stewart, J.E.
 408 Van Eyk, J.G. Braun, S. Cheng, and K. Sobhani. 2021. Antibody responses to the
 409 BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nat Med*
- Eijsvoogel, N.B., M.I. Hollegien, V.L.A. Bok, A.G. Derksen Lubsen, F.P.J. Dikken, S.A.C.A. Leenders,
 A. Pijning, E. Post, M. Wojciechowski, M. Hilbink, and E. de Vries. 2017. Declining
 antibody levels after hepatitis B vaccination in Down syndrome: A need for booster
 vaccination? J Med Virol 89:1682-1685.
- 414 Esparcia-Pinedo L, Martínez-Fleta P, Ropero N, Vera-Tomé P, Reyburn .H. T, Casasnovas J. M.,
 415 Rodríguez-Frade JM, Vales-Gomez. M, Vilches C, Martin-Gayo E, Muñoz-Calleja C,

416	Sanchez-Madrid F, and Alfranca A. 2022. CD4+ T cell Immune specificity changes after
417	vaccination in healthy and COVID-19 convalescent subjects. In Frontiers in Immunology.
418	Espinosa, J.M. 2020. Down Syndrome and COVID-19: A Perfect Storm? <i>Cell Rep Med</i> 1:100019.
419	Franciotta, D., A. Verri, E. Zardini, L. Andreoni, M. De Amici, R. Moratti, and L. Nespoli. 2006.
420	Interferon-gamma- and interleukin-4-producing T cells in Down's syndrome. Neurosci
421	Lett 395:67-70.
422	Grifoni, A., D. Weiskopf, S.I. Ramirez, J. Mateus, J.M. Dan, C.R. Moderbacher, S.A. Rawlings, A.
423	Sutherland I. Premkumar, R.S. Jadi, D. Marrama, A.M. de Silva, A. Frazier, A.F. Carlin,
474	LA Greenbaum B Peters F Krammer D.M. Smith S Crotty and A Sette 2020 Targets
425	of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
425	Linexposed individuals <i>Cell</i> 181:1489-1501 e1415
420	Hinnisley-Cox I. C.A. Countand N. Mehta, P.H. Keogh, K. Diaz-Ordaz, K. Khunti, P.A. Lyons, F.
427 110	Koo A Shoikh S Pahman I Valabbii E M Harrison D Sollon N Hag M G Somple
420	Ree, A. Sheikii, S. Rahman, J. Valabiiji, E.W. Hamson, P. Sellen, N. Hay, W.G. Semple,
429	P.W.W. Johnson, A. Hayward, and J.S. Nguyen-Van-Tam. 2021. Risk prediction of covid-
430	19 related death and hospital admission in adults after covid-19 vaccination: national
431	prospective cohort study. BMJ 374:n2244.
432	Huggard, D., D.G. Doherty, and E.J. Molloy. 2020. Immune Dysregulation in Children With Down
433	Syndrome. Front Pediatr 8:73.
434	Hüls, A., A.C.S. Costa, M. Dierssen, R.A. Baksh, S. Bargagna, N.T. Baumer, A.C. Brandão, A. Carfi,
435	M. Carmona-Iragui, B.A. Chicoine, S. Ghosh, M. Lakhanpaul, C. Manso, M.A. Mayer, M.
436	Del Carmen Ortega, D.R. de Asua, A.S. Rebillat, L.A. Russell, G. Sgandurra, D. Valentini,
437	S.L. Sherman, and A. Strydom. 2020. An international survey on the impact of COVID-19
438	in individuals with Down syndrome. <i>medRxiv</i>
439	Hüls, A., A.C.S. Costa, M. Dierssen, R.A. Baksh, S. Bargagna, N.T. Baumer, A.C. Brandão, A. Carfi,
440	M. Carmona-Iragui, B.A. Chicoine, S. Ghosh, M. Lakhanpaul, C. Manso, M.A. Mayer,
441	M.D.C. Ortega, D.R. de Asua, A.S. Rebillat, L.A. Russell, G. Sgandurra, D. Valentini, S.L.
442	Sherman, A. Strydom, and T.R.C Initiative. 2021. Medical vulnerability of individuals
443	with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society
444	and the UK ISARIC4C survey. EClinicalMedicine 33:100769.
445	Joshi, A.Y., R.S. Abraham, M.R. Snyder, and T.G. Boyce. 2011. Immune evaluation and vaccine
446	responses in Down syndrome: evidence of immunodeficiency? <i>Vaccine</i> 29:5040-5046.
447	Kong, X.F., L. Worley, D. Rinchai, V. Bondet, P.V. Jithesh, M. Goulet, E. Nonnotte, A.S. Rebillat.
448	M. Conte C. Mircher, N. Gürtler, I. Liu, M. Migaud, M. Elanbari, T. Habib, C.S. Ma, L.
449	Bustamante I Abel A Ravel S Lyonnet A Munnich D Duffy D Chaussabel II
450	Casanova S.G. Tangve S. Boisson-Dunuis and A. Puel 2020. Three Conjes of Four
450 //51	Interferon Recentor Genes Underlie a Mild Type Unterferon on athy in Down Syndrome
451	I Clin Immunol 40:907 910
4JZ 4E2	Malle L and D Regunavic 2021 Down syndrome and type Linterferent net se simple. Curr
433	Onin Immunol 72:106-205
454 455	Opin minutor 72.190-205.
455	Mateus, J., A. Gritoni, A. Tarke, J. Siuney, S.I. Ramirez, J.W. Dan, Z.C. Burger, S.A. Rawlings, D.W.
456	Smith, E. Phillips, S. Maliai, M. Lammers, P. Rubiro, L. Quiambao, A. Sutherland, E.D. Yu,
457	R. da Silva Antunes, J. Greenbaum, A. Frazier, A.J. Markmann, L. Premkumar, A. de Silva,
458	B. Peters, S. Crotty, A. Sette, and D. Weiskopf. 2020. Selective and cross-reactive SARS-
459	CoV-2 T cell epitopes in unexposed humans. <i>Science</i> 370:89-94.
460	Narasimhan, M., L. Mahimainathan, E. Araj, A.E. Clark, J. Markantonis, A. Green, J. Xu, J.A.
461	SoRelle, C. Alexis, K. Fankhauser, H. Parikh, K. Wilkinson, A. Reczek, N. Kopplin, S.
462	Yekkaluri, J. Balani, A. Thomas, A.G. Singal, R. Sarode, and A. Muthukumar. 2021. Clinical
463	evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM
464	assays among infected, recovered, and vaccinated groups. J Clin Microbiol
465	Ottaviano, G., J. Gerosa, M. Santini, P. De Leo, A. Vecchione, T. Jofra, C. Trimarchi, M. De
466	Pellegrin, M. Agosti, A. Aiuti, M. Marinoni, M.P. Cicalese, and G. Fousteri. 2020. A

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 467 prevalent CXCR3(+) phenotype of circulating follicular helper T cells indicates humoral
 468 dysregulation in children with Down syndrome. *J Clin Immunol* 40:447-455.
- 469 Pairo-Castineira, E., S. Clohisey, L. Klaric, A.D. Bretherick, K. Rawlik, D. Pasko, S. Walker, N. 470 Parkinson, M.H. Fourman, C.D. Russell, J. Furniss, A. Richmond, E. Gountouna, N. 471 Wrobel, D. Harrison, B. Wang, Y. Wu, A. Meynert, F. Griffiths, W. Oosthuyzen, A. 472 Kousathanas, L. Moutsianas, Z. Yang, R. Zhai, C. Zheng, G. Grimes, R. Beale, J. Millar, B. 473 Shih, S. Keating, M. Zechner, C. Haley, D.J. Porteous, C. Hayward, J. Yang, J. Knight, C. 474 Summers, M. Shankar-Hari, P. Klenerman, L. Turtle, A. Ho, S.C. Moore, C. Hinds, P. 475 Horby, A. Nichol, D. Maslove, L. Ling, D. McAuley, H. Montgomery, T. Walsh, A.C. Pereira, 476 A. Renieri, X. Shen, C.P. Ponting, A. Fawkes, A. Tenesa, M. Caulfield, R. Scott, K. Rowan, 477 L. Murphy, P.J.M. Openshaw, M.G. Semple, A. Law, V. Vitart, J.F. Wilson, J.K. Baillie, G. 478 Investigators, I.C. Investigators, C.-H.G. Initiative, a. Investigators, B. Investigators, and 479 G.-C. Investigators. 2021. Genetic mechanisms of critical illness in COVID-19. Nature 480 591:92-98.
- Perera, B., R. Laugharne, W. Henley, A. Zabel, K. Lamb, D. Branford, K. Courtanay, R. Alexander,
 K. Purandare, A. Wijeratne, V. Radhakrishnan, E. McNamara, Y. Daureeawoo, I.
 Sawhney, M. Scheepers, G. Taylor, and R. Shankar. 2020. COVID-19 deaths in people
 with intellectual disability in the UK and Ireland: descriptive study. *BJPsych Open* 6:e123.
- Prendecki, M., C. Clarke, J. Brown, A. Cox, S. Gleeson, M. Guckian, P. Randell, A.D. Pria, L.
 Lightstone, X.N. Xu, W. Barclay, S.P. McAdoo, P. Kelleher, and M. Willicombe. 2021.
 Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose
 BNT162b2 vaccine. *Lancet* 397:1178-1181.
- Real de Asua, D., M.A. Mayer, M.D.C. Ortega, J.M. Borrel, T.J. Bermejo, D. González-Lamuño, C.
 Manso, F. Moldenhauer, M. Carmona-Iragui, A. Hüls, S.L. Sherman, A. Strydom, R. de la
 Torre, and M. Dierssen. 2021. Comparison of COVID-19 and Non-COVID-19 Pneumonia
 in Down Syndrome. J Clin Med 10:
- Ruan, Q., K. Yang, W. Wang, L. Jiang, and J. Song. 2020. Clinical predictors of mortality due to
 COVID-19 based on an analysis of data of 150 patients from Wuhan, China. In Intensive
 Care Med. 846-848.
- 496 Sadarangani, M., A. Marchant, and T.R. Kollmann. 2021. Immunological mechanisms of vaccine 497 induced protection against COVID-19 in humans. *Nat Rev Immunol* 21:475-484.
- Schoch, J., T.R. Rohrer, M. Kaestner, H. Abdul-Khaliq, L. Gortner, U. Sester, M. Sester, and T.
 Schmidt. 2017. Quantitative, Phenotypical, and Functional Characterization of Cellular
 Immunity in Children and Adolescents With Down Syndrome. *J Infect Dis* 215:16191628.
- Sekine, T., A. Perez-Potti, O. Rivera-Ballesteros, K. Strålin, J.B. Gorin, A. Olsson, S. LlewellynLacey, H. Kamal, G. Bogdanovic, S. Muschiol, D.J. Wullimann, T. Kammann, J. Emgård, T.
 Parrot, E. Folkesson, O. Rooyackers, L.I. Eriksson, J.I. Henter, A. Sönnerborg, T. Allander,
 J. Albert, M. Nielsen, J. Klingström, S. Gredmark-Russ, N.K. Björkström, J.K. Sandberg,
 D.A. Price, H.G. Ljunggren, S. Aleman, M. Buggert, and K.C.-S. Group. 2020. Robust T Cell
 Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell*183:158-168.e114.
- STANDARDIZATION, E.C.O.B. Establishment of the WHO International Standard and Reference
 Panel for anti-SARS-CoV-2 antibody. In WHO/BS/2020.2403.
- Tyllis, T.S., K.A. Fenix, T.S. Norton, E.E. Kara, D.R. McKenzie, S.C. David, M. Alsharifi, D. Yu, S.R.
 McColl, and I. Comerford. 2021. CXCR5. *Front Immunol* 12:626199.
- 513 Valentine, K.M., and K.K. Hoyer. 2019. CXCR5+ CD8 T Cells: Protective or Pathogenic? *Front* 514 *Immunol* 10:1322.
- Valentini, D., V. Marcellini, S. Bianchi, A. Villani, M. Facchini, I. Donatelli, M.R. Castrucci, E.
 Marasco, C. Farroni, and R. Carsetti. 2015. Generation of switched memory B cells in

517 response to vaccination in Down syndrome children and their siblings. *Vaccine* 33:6689-

518 6696.

- 519 Wadman, M. 2020. People with Down syndrome face high risk from coronavirus. *Science* 520 370:1384-1385.
- Woldemeskel, B.A., A.K. Kwaa, C.C. Garliss, O. Laeyendecker, S.C. Ray, and J.N. Blankson. 2020.
 Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2. *J Clin*
- 523 *Invest* 130:6631-6638.

524

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

525

526 **FIGURE LEGENDS**

Figure 1. T cell response in Down Syndrome patients after SARS-CoV-2 vaccination. SARS-CoV-2-specific CD4+ (A.) and CD8+ (B.) lymphocytes in DS patients in Visit 0, Visit 1 and Visit 2. *Upper panels*, pie charts indicate the percentage of patients with (black) or without (white) T cell immunity against SARS-CoV-2 in each visit. *Lower panels*, number of patients with T cell response against specific peptide pools in each visit.

Figure 2. T helper subsets in Down Syndrome patients after SARS-CoV-2 vaccination. A., *Left*, percentage of SARS-CoV-2-specific Th1 and Th2 CD4+ lymphocytes in visits 1 (V1) and 2 (V2); *right*, percentage of SEB-activated Th1 and Th2 CD4+ cells in visits 1 and 2. **B.**, Graphics show the percentage of S1-specific (*left*) and S2-specific (*right*) Th1 and Th2 CD4+ subsets in visits 1 and 2. Mean+SD is shown. *p<0.05; **p<0.01; ns, non-significant.

Figure 3. Circulating Tfh in Down Syndrome patients after SARS-CoV-2 vaccination. A., Graphics show the percentage of circulating CD4+CXCR5+ (*left*) and CD4+CXCR5+PD-1hi (*right*) cells in visits 1 and 2. Mean+SD is shown. B., Graphics show the percentage of SARS-CoV-2-specific CD8+CXCR5+ (*left*) and PD-1hi expression within CD8+CXCR5+ population (*right*) in visits 1 and 2 (n=11). *p<0.05; **p<0.01; ns, non-significant.

Figure 4. Humoral response in Down Syndrome patients after SARS-CoV-2 vaccination. A., Percentage of DS donors with detectable anti-SARS-CoV-2 S IgG in visits 0, 1 and 2. B., Specific anti-SARS-CoV-2 S IgG titers in DS patients in visits 0 (V0), 1 (V1), and 2 (V2). C., Specific anti-SARS-CoV-2 S IgG titers in visits 0 (V0), 1 (V1), and 2 (V2) in DS patients \leq 40 years (*left*) or> 40 years (*right*). ****p<0.0001; ***p<0.001; ns, non-significant.

551

552

TABLE 1. Demographic and clinical characteristics of the study sample 553

554

	n = 55	
Age (years)	44 ± 10	
Sex (male)	25 (44%)	
Living situation		
Family home	31 (55%)	
Supervised group home	1 (2%)	
Institutionalized	11 (20%)	
Degree of intellectual disability		
Mild	45 (80%)	
Moderate	9 (16%)	
Severe	2 (4%)	
Comorbidities ^(&)		
Skin conditions	36 (64%)	
Hypothyroidism	29 (51%)	
Gastrointestinal disorders	21 (37,5%)	
Obstructive sleep apnea	19 (34%)	
Congenital heart disease	10 (18%)	
Alzheimer's disease	11 (20%)	
Epilepsy	2 (4%)	
Vaccine type		
BNT162b2 (Comirnaty®, Pfizer/BioNTech)	48 (86%)	
mRNA-1273 (Spikevax®, Moderna)	7 (12,5%)	
ChAdOx1 (Vaxzevria®, Oxford/Astra Zeneca)	1 (1,5%)	
Adverse reactions (#)		
To first vaccine dose	6 (11%)	
To second vaccine dose	6 (11%)	
History of COVID-19 before vaccination	14 (25%)	
Vaccinated in the past 12 months ^(*)	10 (18%)	

555 (&): Only comorbidities that have been linked to a worse prognosis of SARS-CoV-2 infection or to immune dysregulation are presented. 556

557 (#): Noted adverse reactions were all mild (involving either local pain, fever or malaise, 558 lasting less than 24 h).

(*): Other than vaccination against SARS-CoV-2 (i.e., influenza or pneumococcal 559

- vaccination) 560
- 561

FIGURES

Figure 1









TOTAL-PEPTIDE SPECIFIC SUBSETS



SEB-RESPONSIVE TH SUBSETS





Figure 3







В





Figure 4



С







